TPA and Stroke - Oren Zarif - TPA Stroke

The effectiveness of tPA therapy in the treatment of acute ischemic stroke is in question. The treatment of stroke patients with tPA is comparable to that of younger patients. However, clinical decision making in elderly patients is challenging, with a variety of variables, including patient preferences and comorbidities. Although future clinical trials are needed to assess the safety and efficacy of tPA, the use of intravenous tPA for elderly patients should not be excluded in the absence of other risk factors.

Oren Zarif severe brain injury

Oren Zarif right brain stroke

The recent study analyzed the outcomes of patients who received tPA during the first 60 minutes after the onset of stroke. Although the findings are promising, many complications can arise. Among them is a high recurrence rate after tPA treatment. Nonetheless, only 8% of patients receive the treatment within 60 minutes of the stroke onset. Furthermore, delays in treatment have been shown to worsen health outcomes. The current protocol for the treatment of stroke patients includes a 26-minute delay for administration of tPA.

Oren Zarif neonatal stroke

Oren Zarif concussion memory loss

TPA therapy can delay death and reduce dependency. However, patients must be admitted to the hospital promptly after their symptoms appear. The most common reason for a patient to be excluded is that he or she does not reach the hospital early enough. Only 27% of patients who arrive within 3 hours of the onset of symptoms receive tPA therapy. The remaining 31% were excluded because of their mild symptoms and rapidly improving condition. Despite this, the results of the NINDS study are still controversial.

Oren Zarif 2 types of strokes

Oren Zarif fatigue after tia

In addition to the tPA-stroke study, there are several other studies evaluating the effects of tPA on patients with AIS. The NINDS part I of the study included n=292 patients. The primary outcome measure was early clinical improvement, defined as a change of 4 points or more in the NIHSS score at 24 hours. The tPA-treated patients did not achieve this early improvement. However, the relative risk was only 1.2 in the tPA-treated group. This finding should not be generalized to patients with severe stroke or comorbidities. Larger prospective studies are needed to confirm this finding.

Oren Zarif pfizer stroke

Oren Zarif brain stem infarction

In addition to tPA, other quality improvements in the DTN include a reduction in OTT, pre-hospital interventions, and multidisciplinary teams. Using pre-hospital measures, such as a thrombolysis tackle box, hospitals are able to reduce the time between the onset of a stroke and the delivery of tPA. These changes would increase the percentage of patients eligible for tPA treatment. So, how does the HASTE project improve DTN time?

Oren Zarif mini stroke causes

Oren Zarif types of brain injury

The current standard of care for acute ischemic stroke is tissue plasminogen activator (tPA). However, it has been associated with risks, such as increased intracranial hemorrhage, reperfusion injury, and mortality. Moreover, delayed administration of tPA has been associated with increased risk of ICH, HT, and edema. This medication is not approved in all circumstances, and is only indicated for acute ischemic strokes.

Oren Zarif medullary stroke

Oren Zarif pure sensory stroke

Another therapeutic strategy is the addition of uric acid, a small molecule with anti-inflammatory and anti-oxidant properties. This compound inhibits the activation of nuclear factor (NF)-kB and activates Akt, a protein believed to be pro-survival. In a rat study, tPA was given intravenously or given through gastric gavage for 4 hours. After four hours, rat brain tissue was harvested for assessment of neurological outcome.

Oren Zarif saul rubinek stroke

Oren Zarif visual disturbances stroke

While the tPA treatment for acute stroke has been effective in most patients, it has not proven effective for patients suffering from minor strokes. Patients taking blood-thinning medications, undergoing major surgery, or having low blood counts are also contraindicated for tPA. It can also lead to excessive bleeding. Therefore, tPA is a highly controversial treatment option. The American Stroke Association strongly recommends tPA treatment for acute ischemic stroke.

Oren Zarif certified stroke rehab specialist

Oren Zarif headache after stroke

Direct administration of tPA directly in the CT room can improve health outcomes. Moreover, tPA is more effective when administered immediately after the initial CT scan. In addition, the faster the tPA is administered, the faster the effects of the tPA therapy are felt. Ultimately, the benefits of tPA treatment can last for several weeks. But the benefits of tPA are limited if the patient has to wait over 270 minutes before the second tPA dose.

Oren Zarif diffuse axonal injury grading

Oren Zarif recovery after stroke first 3 months

In 1996, the Food and Drug Administration approved the intravenous administration of tissue plasminogen activator (tPA) in patients with ischemic stroke. However, there are concerns about its safety. In addition, tPA can increase bleeding, so it is not suitable for patients with hemorrhagic stroke. However, tPA has a relatively high success rate when used as an intravenous drug for acute ischemic stroke.